Introduction {#Sec1}
============

Carpal tunnel syndrome (CTS) is the most common compression neuropathy, with a population prevalence of 4%, which is higher in women (3--5.6%) than in men (0.6--2.8%) \[[@CR1], [@CR2]\]. It is due to the compression of the median nerve in the passage through the carpal tunnel in the wrist. It is diagnosed with clinical criteria and electrophysiological studies, which are objective and quantitative, and have been recognized to be highly sensitive and specific for the assessment of nerve function in CTS patients \[[@CR2]\].

CTS therapies can be conservative or surgical, but it remains unclear to physicians when it needs treatment, if the severity is low, and how to make a decision regarding surgical treatment \[[@CR2]\]. Surgical treatment is indicated in severe cases. In general, conservative management of CTS includes avoiding all provoking factors, correcting potential medical illnesses that can determine CTS (hypothyroidism or diabetes), use of wrist splints, non-steroidal anti-inflammatory drugs, corticosteroids, vitamin B12 and, recently, the use of palmitoylethanolamide (PEA) has been introduced \[[@CR1]\].

PEA, first described in 1957 \[[@CR3]\], is an endogenous fatty acid amide that has shown anti-inflammatory activity in different experimental models \[[@CR1], [@CR4]--[@CR7]\], as well as analgesia in acute and inflammatory pain \[[@CR1], [@CR8], [@CR9]\] and neuroprotection \[[@CR1], [@CR10]--[@CR13]\]. Probably due to the fact that PEA is an endogenous modulator as well as a compound in food, such as eggs and milk, no serious side-effects or any drug interactions have been reported \[[@CR3], [@CR10]\].

Clinical trials have evaluated the efficacy and safety of PEA in nerve compression, especially in sciatic pain and pain due to carpal tunnel syndrome \[[@CR3]\]. However, it can be useful in other peripheral neuropathies such as chemotherapy-induced peripheral neuropathy, diabetic neuropathy, osteoarthritis, failed back surgery syndrome, dental pain, neuropathic pain in strokes, multiple sclerosis, chronic pelvic pain, post-herpetic neuralgia and vaginal pain \[[@CR10]\]. The published literature on the clinical use of PEA is scarce but some authors have reported good results with PEA in the treatment of several peripheral neurological conditions. Randomized controlled studies are needed to clarify the role of PEA in the treatment of such conditions.

The aim of the present study is to prove the potential efficacy and safety of PEA in the treatment of CTS of low and moderate severity by analyzing clinical and electrophysiological changes.

Materials and methods {#Sec2}
=====================

A total of 68 patients with a clinical and electrophysiologically confirmed diagnosis of low to moderate carpal tunnel syndrome were recruited for this study and randomly assigned to two groups between February 2011 and September 2014. The study was previously approved by the Ethics Committee of our Institution. Patients with a history of upper extremity surgery, currently taking steroids, using night splinting or with food allergies were excluded. Inclusion criteria were patients aged between 18 and 75 years who were suffering from low or moderate CTS for at least 3 months and who agreed to participate in the study after providing signed informed consent. Group *N* was given 300 mg of PEA twice a day over 60 days. Group *P* was given a placebo with exactly the same appearance twice a day for the same period. After treatment, electroneurography (ENG) was performed and the patient was clinically evaluated and any complications that presented due to medication were recorded. Two patients did not complete the treatment (one in each group), for causes unrelated to the medication, and five more did not receive a follow-up ENG due to refusal or losing the report. The remaining 61 patients included 18 females and 12 males in group *N*, and 19 females and 12 males in group *P*. In 36 cases, the right hand was affected and in 25 cases the left hand was affected. Associated pathologies included fibromyalgia in 3 cases in group *N*.

The severity of symptoms and functional impairment of the patients were assessed using a Spanish translation of Levine's questionnaire \[[@CR14], [@CR15]\] before and after treatment. This tool has good validity, reliability and responsiveness \[[@CR16]\] and is recommended as an assessment instrument for research in CTS \[[@CR17]\]. The symptom severity scale (SSS) refers to the first 11 questions and the functional status scale (FSS) refers to the last 8 questions of this questionnaire. A clinical examination including Durkan's test \[[@CR18]\] and Phalen's test \[[@CR19]\] was performed at these two time points, and the presence of paresthesia was also recorded. A second ENG was also carried out to evaluate any changes in electrophysiological data.

The results were analyzed using the R statistical package \[[@CR20]\] with a *p* value of \<0.05. The two groups were compared for differences in the presence of males and females, the average age, weight, body mass index (BMI) and pre-treatment data including Durkan's test, Phalen's test, pain in a visual analog scale (VAS), Levine's questionnaire, and differences in electrophysiological data. The *t* test was used for data that followed a normal distribution and the Wilcoxon rank sum test with continuity correction was used for quantitative data. Qualitative data were assessed with chi-squared test.

The results of the two groups after treatment regarding VAS, Levine's questionnaire, clinical examination and electrophysiological data were then compared using the *t* test. The results in each group before and after treatment were compared using the test for paired data. The differences in numerical data before and after treatment were compared using the *t* test.

Results {#Sec3}
=======

The demographic (Table [1](#Tab1){ref-type="table"}), clinical and electrophysiological data of the two groups showed no statistical differences before treatment (Table [2](#Tab2){ref-type="table"}a). The mean values and standard deviation for age, weight and BMI in both groups were 51.76 (±11.12), 72.76 (±9.54) and 28.19 (±3.24) for group *N* and 53.32 (±13.43), 72.43 (±13.03) and 28.85 (±4.84) for group *P* (Table [1](#Tab1){ref-type="table"}). No complications due to the medication were recorded in either group. After treatment, there were no differences in either group compared to the initial status regarding Durkan's test, Phalen's test, VAS, and electrophysiological data (Table [2](#Tab2){ref-type="table"}b). The differences in the most important measurements for the evaluation of CTS before and after treatment are shown in Table [3](#Tab3){ref-type="table"}. For example, the VAS score diminished 0.5 points in group *N* and 0.8 points in group *P*. None of these measurements show a statistically significant improvement in either group. Levine's questionnaire showed better results in both groups (Table [4](#Tab4){ref-type="table"}) with a statistically significant improvement in only the SSS for group *P* (*p* value of 0.002809) and improvement in the FSS (*p* value of 0.03334) and SSS (*p* value of 0.005) for group *N*. This improvement was not statistically significant between the two groups (Table [2](#Tab2){ref-type="table"}b).Table 1Average values of demographic data of both groups (SD in brackets)Group *N*Group *Pp* valueAge51.76 (11.12)53.32 (13.43)0.6248Weight72.76 (9.54)72.43 (13.03)0.9104BMI28.19 (3.24)28.85 (4.84)0.5345 Table 2Average data (a) before treatment in both groups (SD in brackets), (b) after treatment in both groups (SD in brackets)Group *N*Group *Pp* value(a) Positive Phalen's test490.1344 (*χ* = 2.2406) Positive Durkan's test17180.9121 (*χ* = 0.0121) VAS4.26 (3.41)4.06 (3.42)0.8182 (*t* = 0.2309) FSS2.03 (0.75)2.24 (0.66)0.2469 (*t* = −1.1696) SSS2.59 (0.76)2.57 (0.74)0.9217 (*t* = 0.0988) Sensitive latency3.41 (0.99)3.32 (1.01)0.7328 (*t* = 0.343) Sensitive peak amplitude10.82 (10.39)8.86 (5.42)0.3671 (*t* = 0.9091) Sensitive speed40.15(8.08)40.53 (7.05)0.8479 (*t* = 0.1927) Motor latency4.01 (0.96)3.87 (0.91)0.5936 (*t* = 0.5372) Motor peak amplitude7.87 (3.7)7.98 (3.06)0.9148 (*t* = −0.1076)(b) Positive Phalen's test9130.3812 (*χ* = 0.7667) Positive Durkan's test21190.4741 (*χ* = 0.5123) VAS3.76 (3.19)3.25 (3.18)0.5356 (*t* = 0.6231) FSS1.80 (0.81)1.96 (0.77)0.4329 (*t* = −0.7896) SSS2.25 (0.86)2.11 (0.81)0.5078 (*t* = 0.6663) Sensitive latency3.33 (0.81)3.55 (1.6)0.5264 (*t* = −0.638) Sensitive peak amplitude10.93 (7.65)11.12 (6.13)0.9208 (*t* = −0.1) Sensitive speed38.39 (7.87)42.00 (8.54)0.128 (*t* = −1.5489) Motor latency3.82 (0.63)3.71 (0.7)0.5867 (*t* = 0.5478) Motor peak amplitude8.45 (2.74)8.23 (2.43)0.7922 (*t* = 0.2652) Table 3Differences in parameters before and after treatment (SD in brackets)*NPp* valueVAS−0.5 (2.8)−0.8 (3.08)0.6867 (*t* = 0.40527)FSS−0.22 (0.55)−0.27 (0.87)0.7831 (*t* = 0.2765)SSS−0.33 (0.6)−0.45 (0.78)0.4889 (*t* = 0.69646)Sensitive latency−0.1346 (1.4)0.4026 (1.27)0.1551 (*t* = −1.4435)Sensitive peak amplitude−0.065 (13.28)1.198 (5.22)0.6601 (*t* = 0.44248)Sensitive speed−1.21 (7.49)2.13 (9.08)0.1707 (*t* = −1.3918)Motor latency−0.124 (0.44)−0.057 (0.41)0.6366 (*t* = 0.47649)Motor peak amplitude−0.2413 (2.94)0.0368 (2.89)0.7887 (*t* = −0.2702) Table 4Comparison of pre-treatment and post-treatment changes in each group (SD in brackets)Pre-treatmentPost-treatment*p* valueFSS group *N*2.03 (0.75)1.80 (0.81)0.03334\*FSS group *P*2.24 (0.66)1.96 (0.77)0.08656SSS group *N*2.59 (0.76)2.25 (0.86)0.005\*SSS group *P*2.57 (0.74)2.11 (0.81)0.002809\*Statistically significative data are indicated

Discussion {#Sec4}
==========

Nerve pressure induces inflammation of nerves and nerve roots, neuritis and radiculitis. Subsequently, they progress into a more chronic pathological state due to the induction of a number of cascades of chemical inflammatory reactions \[[@CR21]\]. Inflammatory cells, such as activated mast cells, play an important role in nerve compression syndromes and are one of the sources of pro-inflammatory prostaglandins and cytokines \[[@CR22]\].

Neuropathic pain is challenging to manage and different conservative treatments have been proposed in patients with mild to moderate CTS, such as the use of splinting the wrist, ultrasonic therapy, laser therapy, oral steroids, non-steroidal anti-inflammatory drugs, oral vitamin B6, local injection of corticosteroids and work place modifications. Clinical studies have confirmed that a significant short-term benefit could be gained with some of these treatments \[[@CR23]--[@CR27]\]. Although a steroid injection into the wrist is often successful, a major complication such as iatrogenic injury to the median nerve is possible \[[@CR28]\].

Some clinical studies suggested an anti-edema and analgesic effect of PEA \[[@CR7], [@CR29], [@CR30]\] that could be useful in the conservative treatment of mild and moderate CTS with a low risk of complications. PEA is a safe medication that can be used in the treatment of different compression neuropathies \[[@CR31]\] as well as neuropathic pain due to diabetes or trauma \[[@CR32]\].

PEA has been used effectively for low-grade CTS, together with other treatment measures. While a daily dose of 600 mg has been effective in other compression neuropathies, our work with this dose in CTS has proved to be insufficient. However, a daily dose of 1200 mg for two months has been proved to be effective in the treatment of CTS associated with diabetes \[[@CR33]\]. This is in contrast to work by Conigliaro et al. \[[@CR1]\], who reported a clinical improvement and a reduction of median nerve latency time in ENG after treatment with both 600 and 1200 mg of PEA for one month in moderate CTS. This study included a control group but was not blinded, since this group received no treatment. In addition, this study included only 26 patients in total.

There is no electrodiagnostic test that can be considered gold standard. Even a combination of clinical and electrodiagnostic tests does not have sufficient evidence of providing the best performance for CTS diagnosis and grading \[[@CR34]\]. However, sensory nerve conduction to the median nerve with distal latency and median motor nerve conduction used in our study are measures that are recommended for electrodiagnostic testing \[[@CR35]\].

Our study was designed as a prospective double-blinded randomized trial which would avoid the placebo effect of taking a medication, i.e., the bias of the patient considering he had had an improvement just because he was taking a treatment. Another strong point of our study is that the number of patients is much higher than all of the other studies we have cited. This makes us consider our clinical data to be very reliable. These data indicate a slight clinical improvement in the questionnaire results that needs to be studied further using higher doses of PEA. In contrast, electrodiagnostic testing could introduce some doubts into the results when compared to the results of other published studies; we did not find any changes but other authors have done so, albeit with a small number of patients.

The treatment of mild to moderate CTS includes several therapies that can be combined. A safe medication for a limited time appears to be an appealing option in the treatment of CTS; however, PEA does not seem to fulfill these requirements at the moment. It clearly seems to be a safe medication but its dosage and real effect need further study.
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